In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication

Molecular Therapy

Volumn 9, Issue 2, 2004, Pages 160-172

  Davis, Brian M ^a   Humeau, Laurent ^a   Dropulic, Boro ^a,b  

^a VIRxSYS Corporation   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Gene therapy; HIV; Lentivirus; MGMT; Selection; Stem cell; T lymphocyte

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; CD4 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; LEUKOSIALIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL LINEAGE; CELL SELECTION; COLONY FORMING UNIT; CONTROLLED STUDY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; SCID MOUSE; STEM CELL MOBILIZATION; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

LENTIVIRUS; MURINAE;

EID: 1342290228     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.11.003     Document Type: Article

References (36)

1. Joint United Nations Programme on HIV/AIDS (2003). AIDS Epidemic Updates. WHO/UNAIDS, Geneva.
2. Centers for Disease Control and Prevention (2001). HIV/AIDS Surveillance Report, Vol. 13. CDC, Atlanta.
3. th International Workshop on HIV Drug Resistance (2002). Rapid Report. Seville, July 2-5, 2002.
4. Little, S. J., et al. (2002). Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347: 385-394.
5. Vigouroux, C., et al. (1999). Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25: 383-392.
6. Behrens, G. M., Stoll, M., and Schmidt, R. E. (2000). Lipodystrophy syndrome in HIV infection. Drug Saf. 23: 57-76.
7. Powderly, W. G. (2002). Long term exposure to lifelong therapies. J. Acquired Immune Defic. Syndr. 29: S28-S40.
8. MacGregor, R. R. (2001). Clinical protocol: a phase I open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum. Gene Ther. 12: 2028-2029.
9. Dropulic, B., Hernankova, M., and Pitha, P. M. (1996). A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl. Acad. Sci. USA 93: 11103-11108.
10. Walker, R. E., et al. (1998). Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 92: 1131-1141.
11. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8: 47-53.
12. Muul, L. M., et al. (2003). Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101: 2563-2569.
13. Aiuti, A., et al. (2002). Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat. Med. 8: 423-425.
14. Malech, H. L., et al. (1997). Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 94: 12133-12138.
15. + cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9: 2629-2640.
16. Kohn, D. B., et al. (1999). A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94: 368-371.
17. Cowan, K. H., et al. (1999). Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin. Cancer Res. 5: 1619-1628.
18. Hesdorffer, C., et al. (1998). Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16: 165-172.
19. Cavazzana-Calvo, M., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
20. Abonour, R., et al. (2000). Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat. Med. 6: 652-658.
21. Sorrentino, B.P., et al. (1992). Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. 257: 99-103.
22. Podda, S., et al. (1992). Transfer and expression of the human multiple drug resistance gene into live mice. Proc. Natl. Acad. Sci. USA 89: 9676-9680.
23. Corey, C. A., DeSilva, A. D., Holland, C. A., and Williams, D. A. (1990). Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75: 337-343.
24. Allay, J. A., et al. (1998). In vivo selection of retrovirally transduced hematopoietic stem cells. Nat. Med. 4: 1136-1143.
25. 6-benzylguanine and 1,3-bis(2-chloroethyl )-1-nitrosourea. Cancer Res. 57: 5093-5099.
26. Davis, B. M., Koc, O. N., and Gerson, S. L. (2000). Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95: 3078-3084.
27. Ragg, S., et al. (2000). Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60: 5187-5195.
28. 6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol. Ther. 3: 78-87.
29. 6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum. Gene Ther. 10: 2769-2778.
30. Molina, A., et al. (2000). High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 89: 680-689.
31. 6-benzylguanine plus BCNU. Blood 88: 1649-1655.
32. + hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol. Ther. 5: 381-387.
33. Persons, D. A., et al. (2003). Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically-modified, drug-resistant hematopoietic stem cells. Blood 102: 506-513.
34. Neff, T., et al. (2003). Efficient in vivo selection of hematopoietic stem cells in a large animal model using MGMT and O6BG/temozolomide. ASGT (Abstract).
35. Adachi, A., et al. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59: 284-291.
36. + cells. Blood 99: